💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rituximab

CHEMBL1201576 Phase 4 معتمد Antibody
Half-Life
22 days
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A monoclonal antibody that targets the CD20 protein on B cells, used to treat various B-cell lymphomas, leukemias, and autoimmune conditions like rheumatoid arthritis. It depletes CD20-positive B cells through multiple immune mechanisms, including antibody-dependent cellular cytotoxicity.

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Rheumatoid Arthritis Generalized Anxiety Disorder Melanoma Oncology Systemic Lupus Erythematosus Multiple Sclerosis Lymphoma Hypertension Breast Cancer Hepatitis C Prostate Cancer Colorectal Cancer Leukemia

تصنيفات الأدوية

L — L - Antineoplastic and Immunomodulating Agents

آلية العمل

Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics (PK)

Half-Life 22 days

Pharmacodynamics (PD)

الآلية

Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A monoclonal antibody that targets the CD20 protein on B cells, used to treat various B-cell lymphomas, leukemias, and autoimmune conditions like rheumatoid arthritis. It depletes CD20-positive B cells through multiple immune mechanisms, including antibody-dependent cellular cytotoxicity.

Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Key pharmacokinetic parameters for Rituximab: Half-life: 22 days.

Yes, Rituximab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

ADME Journey →

Related Drugs

Same Drug Class

Methotrexate Small molecule Tamoxifen Small molecule Cyclosporine Protein Tacrolimus Small molecule
{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201576. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.